We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Genentech Inc. is the result of a third-phase Tecentriq trial announcing positive results from chemotherapy of carboplatin and paclitaxel for previously untreated advanced non-squamous non-small cell lung cancer (NSCLC).